Dainippon Sumitomo Prepares 2011 Schizophrenia Drug Launch In The U.S.
This article was originally published in PharmAsia News
Major Japanese drug maker Dainippon Sumitomo will establish a holding company in the U.S. in July to prepare for an NDA submission to U.S. FDA for novel schizophrenia drug lurasidone (SM-13496). The company plans to submit the NDA for the antipsychotic agent with FDA in the first half of 2010, said President Masayo Tata, June 15. According to Dainippon Sumitomo, late-stage clinical trials for lurasidone resulted in promising results in confirming the drug's efficacy and safety, which prompted the company to move up the planned launch date in the U.S. from 2012 to 2011. (Click here for more - Japanese Language
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.